Antibody Drug Conjugates (ADCs) are a novel class of therapeutic proteins that combine the desirable properties of monoclonal antibodies with the cell killing activity of cytotoxic drugs, reducing systemic toxicity and increasing the therapeutic benefit for patients.
We have developed proprietary traceless site-specific linkage technologies to conjugate Philochem’s novel drugs to Philogen’s human monoclonal antibodies that have progressed to advanced clinical trials. Furthermore, we have developed avenues for the generation of potent ADC products based on antibodies which do not internalize into tumor cells.
Certain ADC products are being developed under a licensing deal with Pfizer.
Gébleux et al. (2015) Mol. Cancer Ther. 14:2606-12;
Perrino et al. (2014) Cancer Res. 74:2569-2578;
Gutbrodt et al. (2014) Mol. Cancer Ther. 13:1772-1776;
List et al. (2014) Mol. Cancer Ther. 13:2641-2652;
Casi et al. (2012) JACS 134:5887-5892;
Casi et al. (2012) J Control Release 161: 422-428;
Bernardes et al. (2012) Angewandthe Chemie Int. Ed. Engl. 51:941-94